Skip to content

Dexmedetomidine alleviates intestinal function inhibition in patients undergoing laparoscopic hepatocellular carcinoma resection

Dexmedetomidine alleviates intestinal function inhibition in patients undergoing laparoscopic hepatocellular carcinoma resection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083524
Enrollment
Unknown
Registered
2024-04-26
Start date
2024-04-28
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Sponsors

Beijing Youan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age 18 ~65 years old. (2) B-ultrasound, liver stiffness measurement (LSM), CT and other imaging tests suggested cirrhosis. (3) Child-Pugh grade A. (4) The maximum diameter of liver tumor is less than 5cm (5) Patients undergoing laparoscopic surgery.

Exclusion criteria

Exclusion criteria: (1) Age 65 years. (2) Laparotomy or conversion to laparotomy. (3) Child-Pugh grade B or C. (4) Combined with serious chronic pulmonary insufficiency, renal insufficiency and other diseases. (5) Serious infection, such as sepsis. (6) Complicated with serious cardiovascular and cerebrovascular diseases, such as stroke history, myocardial infarction history, etc. (7) Do not sign informed consent.

Design outcomes

Primary

MeasureTime frame
Time of first postoperative anal exhaust;

Secondary

MeasureTime frame
Monitoring of electroenterogram;borborygmus;Intestinal barrier function;Pain VAS score;Liver function;

Countries

China

Contacts

Public ContactZhang Benhou

Beijing Youan Hospital, Capital Medical University

benhouzhang@ccmu.edu.cn+86 136 0129 3049

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026